akr1a1b Antibody

Basic Research Questions

• What is AKR1A1B and how does it relate to the AKR protein family?

  AKR1A1B belongs to the Aldo-keto reductase (AKR) superfamily, which functions in the reduction of carbonyl-containing compounds to their corresponding alcohols . In zebrafish, AKR1A1B serves as a regulator of gluconeogenesis, controlling glucose homeostasis . The AKR superfamily consists of more than 40 known enzymes and proteins . The human homolog AKR1A1 catalyzes the NADPH-dependent reduction of various carbonyl-containing compounds, with a preference for negatively charged substrates such as glucuronate and succinic semialdehyde . Unlike AKR1B1, which converts glucose to sorbitol, AKR1A1 displays no reductase activity towards retinoids .

• What are the common applications for AKR1A1B antibodies in research?

  AKR1A1B antibodies are primarily used in:

  Application	Common Dilutions	Purpose
  Western Blot (WB)	1:500-1:3000	Protein quantification and expression analysis
  Immunohistochemistry (IHC)	1:50-1:200	Tissue localization studies
  Immunofluorescence (IF/ICC)	1:50-1:500	Cellular localization analysis

  These applications are similar to those used for human AKR1A1 and AKR1B1 antibodies . In zebrafish research, these antibodies are particularly valuable for studying gluconeogenesis regulation and kidney development .

• What is known about AKR1A1B expression patterns in different tissues?

  In zebrafish, AKR1A1B shows highest expression in the liver, with significant expression also detected in the kidneys . The protein plays a critical role in renal function, as evidenced by structural and functional alterations in the pronephros of AKR1A1B mutant embryos . The human homolog AKR1A1 is present in virtually every tissue , while the related AKR1B1 shows elevated expression in various cancer tissues, including gastric cancer, breast cancer, and liver cancer .

• How should AKR1A1B antibodies be stored to maintain optimal activity?

  For optimal preservation of AKR1A1B antibody activity:

  • Store at -20°C, where stability can be maintained for approximately 12 months

  • Avoid repeated freeze/thaw cycles which can degrade antibody quality

  • For antibodies in solution, they are typically supplied in phosphate buffered solution (pH 7.4) containing stabilizers (0.02-0.05%) and glycerol (50%)

  • Some preparations may contain additional stabilizers such as BSA (0.1%)

  • Upon receipt, immediately store at the recommended temperature

Advanced Research Questions

• How can I validate the specificity of an AKR1A1B antibody for my experimental system?

  Validating antibody specificity requires multiple approaches:

  1. Knockout/knockdown controls: Compare antibody reactivity between wild-type and AKR1A1B-knockout/knockdown samples. As demonstrated in zebrafish studies, AKR1A1B knockdown should show diminished signal in immunoblot analysis .

  2. Multiple antibody validation: Use antibodies targeting different epitopes of AKR1A1B. For AKR family proteins, consider antibodies targeting N-terminal (aa 1-150) and mid-region epitopes .

  3. Cross-reactivity assessment: Test for potential cross-reactivity with other AKR family members, particularly AKR1B1, which shares structural similarity. This is critical as antibody cross-reactivities can confound research findings .

  4. Peptide competition assay: Pre-incubate antibody with excess immunizing peptide to confirm signal specificity.

  5. Western blot molecular weight verification: Confirm that the detected band matches the predicted molecular weight of AKR1A1B (approximately 36 kDa for human AKR1A1) .

• What are the methodological considerations when using AKR1A1B antibodies for examining disease mechanisms?

  When investigating disease mechanisms with AKR1A1B antibodies:

  1. Appropriate controls: Include positive control tissues known to express AKR1A1B (e.g., liver tissue for zebrafish studies) .

  2. Antigen retrieval optimization: For IHC applications, optimize antigen retrieval methods as epitope accessibility can affect staining patterns .

  3. Aggregation state consideration: Different aggregation states of proteins can hide epitopes, potentially leading to false-negative results .

  4. Multiple detection methods: Combine immunological detection with functional assays or mRNA expression analysis to correlate protein levels with functional outcomes .

  5. Pathway analysis: When studying AKR1A1B in disease, examine related pathways such as nitrosative stress markers (nitrotyrosine, protein-S-nitrosylation) as observed in zebrafish studies .

• How does AKR1A1B function in gluconeogenesis regulation and what methods can be used to study this role?

  AKR1A1B regulates gluconeogenesis through multiple mechanisms:

  1. PEPCK expression regulation: AKR1A1B controls phosphoenolpyruvate carboxykinase (PEPCK) expression, the rate-limiting enzyme in gluconeogenesis. Loss of AKR1A1B inhibits renal PEPCK expression .

  2. Nitrosative stress modulation: AKR1A1B regulates protein S-nitrosylation, which affects metabolic enzymes. Research methods to study this include:

     • Measuring protein S-nitrosylation levels using biotin switch assay

     • Assessing nitrotyrosine formation via immunoblotting

     • Using NOS inhibitors (e.g., L-NAME) to reverse nitrosative stress effects

  3. Metabolite accumulation analysis: Monitor glucogenic amino acids (particularly glutamate) using metabolomic approaches. In AKR1A1B mutants, glutamate accumulates in kidneys .

  4. Glucose homeostasis assessment: Measure fasting blood glucose levels and glucose tolerance to assess functional consequences of AKR1A1B disruption .

• What are the technical challenges in distinguishing between AKR1A1B and other related AKR family members in experimental settings?

  Key technical challenges include:

  1. Epitope overlap: AKR family members share significant sequence homology. The human AKR1A1 shares 93-94% interspecies antigen sequence with mouse and rat .

  2. Antibody selection: Choosing antibodies that target unique regions is critical. Consider:

     Antibody Type	Target Region	Potential Cross-Reactivity
     N-terminal specific	First 16 amino acids	Minimal cross-reactivity with P3-type fragments
     Mid-region (e.g., 4G8)	Middle sequence	Higher cross-reactivity risk
     C-terminal specific	Terminal sequence	May not detect N-terminal variations

     This principle applies to AKR family proteins as demonstrated in amyloid beta protein research .

  3. Multiple antibody approach: Using multiple antibodies targeting different epitopes can help distinguish between family members .

  4. Mass spectrometry validation: When possible, complement antibody-based detection with mass spectrometry to definitively identify the specific protein .

• How can AKR1A1B research in model organisms be translated to understanding human pathologies?

  Translating AKR1A1B research involves several methodological approaches:

  1. Comparative genomics: Analyze sequence homology between zebrafish AKR1A1B and human AKR1A1. The human AKR1A1 functions as an S-nitroso-CoA reductase similar to zebrafish AKR1A1B .

  2. Pathway conservation assessment: Determine if regulatory pathways (e.g., nitrosative stress regulation) are conserved between species. In both zebrafish and mouse models, AKR1A1 affects protein S-nitrosylation .

  3. Disease model comparisons: Compare phenotypes in zebrafish AKR1A1B mutants with human pathologies:

     • Kidney function alterations in zebrafish AKR1A1B mutants may provide insights into human renal diseases

     • Glucose homeostasis disruption parallels aspects of human metabolic disorders

  4. Human tissue validation: Confirm expression patterns and functional roles identified in model organisms using human tissue samples .

  5. Drug target validation: Test whether inhibitors or activators of AKR1A1B/AKR1A1 identified in model organisms show similar effects in human cell lines or tissues .

• What role does AKR1A1B play in kidney function and how can this be experimentally investigated?

  AKR1A1B is critical for kidney development and function:

  1. Structural assessment: AKR1A1B knockout in zebrafish results in shortened pronephric neck (74.9 ± 19.3 μm in mutants vs. 97.9 ± 14.6 μm in wild-type) .

  2. Functional evaluation methods:

     • Pronephric ultrafiltration assessment using fluorescent dextran injection

     • Histological analysis for detection of hyaline droplets in proximal tubules

     • Electron microscopy for ultrastructural changes

  3. Molecular mechanisms:

     • AKR1A1B regulates nitrosative stress in kidneys

     • Inhibition of nitrosative stress using NOS inhibitors (L-NAME) prevents kidney damage in AKR1A1B mutants

     • AKR1A1B affects PEPCK expression specifically in kidneys, not liver

  4. Metabolic consequences:

     • Accumulation of glucogenic amino acids (glutamate) in kidneys

     • Altered renal gluconeogenesis capacity

     • Changes in protein S-nitrosylation patterns